1. Peptidna bioregulacija
RUSKI PEPTIDI

2. Khavinson Vladimir Khatskelevich
Director of St.Petersburg Institute of Bioregulation and Gerontology of the North Western Dpt. of the Russian Academy of Medical Sciences
Associate Member of the Russian Academy of Medical Sciences, professor, Doctor of Medicine
Honored Scientist of the Russian Federation, Honored Inventor of the Russian Federation
President of International Association of Gerontology and Geriatrics, European Region
Vice-president of Gerontological Society of the Russian Academy of Medical Sciences
Chief gerontologist of the Health Committee of the Government of St.Petersburg
Member of Expert Council of the Public Chamber of the Russian Federation
Member of Expert Council of the Higher Attestation Commission (VAK)
The USSR Council of Ministers' Prize winner, The Ukrainian Academy of Medical Sciences Prize winner, The Ukrainian National Academy of Sciences Prize winner
Paul Ehrlich Medal winner for outstanding achievements in preventive and social medicine, Europäische Akademie der Naturwissenschaften
The author of over 700 scientific publications, including 27 monographs, domestic and international patents
The inventor of 6 pharmaceuticals and 39 peptide bioregulators

3. Quality of the products is guaranteed by the principles of qualitative manufacturing practice "Chemico-Biological Association under the Russian Academy of Medical Sciences "Firma Vita", Ltd.
Highly qualified specialists
The modern system of quality control at all production stages
"Peptide- Bio" product line is produced under the control of developer: St.Petersburg Institute of Bioregulation and Gerontology of the North Western Dpt. of the Russian Academy of Medical Sciences

4. Peptide Bio product line
Cardiogen
Peptide for cardiovascular system
Normoftal
Peptide for visual organs
Bronchogen
Peptide for bronchopulmonary system
Testagen
Peptide for men’s sexual function improvement
Pancragen
Peptide for pancreas
Vesilut
Peptide for urinary system 4

5. The composition of the latest generation of peptide bioregulators
Products are obtained by biological synthesis
NORMOFTAL® AKS-G complex (lysine, glutamic acid)
BRONHOGEN® AKS-B complex
(alanine, glutamic acid, aspartic acid, leucine)
KARDIOGEN® AKS-K complex
(alanine, glutamic acid, aspartic acid, arginine)
VEZILYUT® AKS-M complex
(glutamic acid, aspartic acid)
TESTAGEN® AKS-S complex
(lysine, glutamic acid, aspartic acid, glycine)
PANKRAGEN® AKS-P complex
(lysine, glutamic acid, aspartic acid, tryptophan)

6. of peptide bioregulators
Epigenomic effect
of peptide bioregulators
The scheme of the local separation of chains [poly(dAdT):poly(dAdT)] in consequence of
binding of peptide bioregulator Ala-Glu-Asp-Gly in the major groove of a DNA double helix

7. General action mechanism of peptide bioregulators
Proliferation
Mitosis
Protein synthesis
Restored
cell
Damaged
cell
Peptide bioregulators penetrate into the damaged cells, eliminate the point mutations, stimulate the restoration of the protein synthesis intensity and regulate the expression of genes responsible for cells differentiation and proliferation. As a result, in the target tissue proceed the proliferation of morphologically mature cells with the optimal metabolism level.

8. The cellular effects of peptide bioregulators
A complementary interaction between short peptides and DNA
Chromatin decondensation
Change in genes conformation and expression
Tissue-specific proteins synthesis
Cellular proliferation and differentiation
Regulation of biochemical and physiological processes

9. Mechanism of a short peptide intracellular delivery
PEPTIDE BIOREGULATOR
ПЕПТИДНЫЙ БИОРЕГУЛЯТОР
Small intestine
Portal vein/liver
Target organ
Cell

10. The cellular effects of peptide bioregulators. Summary.
While getting into the nucleus of cells and interacting with specific chromatin loci, the PB regulate the most important steps in the genetic program implementation, such as:
the optimal rate of stem cells division
the maturation of low-differentiated precursor cells with the acquirement of mature cells properties
the maintaining of an optimal range of specific enzymes and receptors in mature cells, thereby regulating their functional state
support of non-specific protective and reparative intracellular systems activity, thereby enhancing cell viability and reducing the apoptosis rate in both normal and pathological conditions

11. The tissue effects of peptide bioregulators. Part 1.
Application of peptide bioregulators allows to optimize the tissue and organic regeneration. An optimization includes:
- the support of the organ or tissue integrity in normal conditions;
- fast and effective recovery from acute or chronic effect of external damaging factors;
- significant reduction in capacity or development rate of pathological regeneration, such as fibrosis, dysplasia, metaplasia, and others
Peptide bioregulators have a protective effect on complementary (TARGET) tissues. It leads to the increase of cells resistance under hypoxic conditions, the toxic effects and other damaging factors. This effect is associated with maintain of a high level of cellular reparative and antioxidant systems activity, and also with number of non-specific protective factors, particularly with the intracellular pool of glutathione.

12. The tissue effects of peptide bioregulators. Part 2.
Peptide bioregulators normalize the tissues metabolism and maintain the optimal number and spectrum of receptors and enzymes in cells. It exerts an influence on the efficiency of nutrients assimilation in tissues and metabolic products removal. Peptide bioregulators have an effect on the complementary organs and tissues functional activity in both normal and pathological conditions.
Peptide bioregulators maintain the metabolism and the optimal number of mature and functionally active cells. It provides the base for: 1) an effective integration of organs and tissues at the level of the entire organism under the influence of other endogenous regulatory systems; 2) an adequate functional adaptation of organs and tissues to the changing needs of the organism.

13. The place of the peptide bioregulators in the therapeutic paradigm
Contemporary therapeutic treatment regimens: combination of drug therapy, diet and recommendations for lifestyle changes
The model of the treatment
regimens development:
«Another brick in the wall» –
the missing link
Anabolic
β-blocker ?
ACE inhibitor
Low molecular
heparine
Statine

14. peptide bioregulators
Cardiology: For example: CHD + arterial hypertension + hypercholesterolemia + CHF
Vasodilators
(В, А, А+В)
Statins and fibrates
Diuretics
Central neurotropic
agents
Antiplatelet
agents
β-Blockers
ACE inhibitors
Organo-specific
peptide bioregulators
Angiotensin I
receptor antagonists
Calcium channel
blockers
Peripheral
neurotropic agents
Anticoagulants

15. Pulmonology: For example: COPD
Detoxication (tobacco, industrial poisons)
Antibiotics
Fluoroquinolones
Bronchodilators: М-acetylcholine receptor antagonists
Indirect
mucokinetics
Bronchodilators: β2-adrenergic agonists
Phospholipase A2 inhibitors
Topical
steroids
Systemic glucocorticoids
Organo-specific
peptide bioregulators
Direct mucokinetics (enzymes)

16. Urology: For example: andropause, spermatogenesis disorders
Urological
disorders
therapy
Nervous
disorders
therapy
Detoxication
(tobacco, alcohol)
Diabetes
therapy
Hormonal
replacement therapy
Organo-specific
peptide bioregulators
Metabolic
syndrome
therapy
Cardiovascular
diseases
therapy
PDE5
inhibitors

17. Endocrinology: For example: the metabolic syndrome, type 2 diabetes
DIET
SPORTS
Thiazolidinediones (pioglitazone)
Biguanides (metformin)
Alpha-glucosidase inhibitors
Organo-specific
peptide bioregulators
Second-generation sulfonylurea medications
Secretagogues (repaglinide)
Incretin
mimetics
B group vitamins

18. The main directions of peptide bioregulators application
Treatment:
inclusion in the
treatment regimens
Post- disease
rehabilitation
Administration to healthy
persons, prolongation of
the working ability period
Geroprotection +
prescription to the
elderly
Peptide
bioregulators
Treatment:
inclusion in the
treatment regimens
Post- disease
rehabilitation
Administration to healthy
persons, prolongation of
the working ability period
Geroprotection +
prescription to the
elderly
Peptide
bioregulators

19. Peptide bioregulators dosage
The preventive dosage is one capsule two times a day. Сourse of administration is 60 days.
Curative dosage is two capsules two times a day. Сourse of administration is from 60 to 120 days, depends on initial patient’s condition.
Dosage recommendations may vary widely. It depends on diagnosis and method of application, such as: health improvement, prophylaxis or the inclusion in the treatment regimens.

20. Peptide bioregulators - 2011
Synthesized products exclude the presence of prions and latent or active viruses exposing to risk of infectious diseases
High purity of a substance
Tissue-specific and organo-specific properties
Don’t provide any stimulation or depression effects on cellular metabolism
Hypoallergenic. No side effects
Supplement of treatment regimen, increase of treatment effect, compatibility with all medications
Can be taken without a prescription
Made in Russia. Patented in 13 countries
The absence of direct competitive products
Bioregulatory therapy is one of the fundamental directions of pharmacology development in area of work-status longevity

21. Therapeutic combinations of peptide regulators / type 2 diabetes
Pancragen
Degenerative lesions of the Langerhans islets and acinar tissue
Normoftal
Diabetic retinopathy, autonomic neuropathy
Type 2
diabetes
Coronary heart disease. Peripheral vascular atherosclerosis
Cardiogen
Diabetic nephropathy + pyelonephritis
Vesilut

22. Therapeutic combinations of peptide regulators / COPD
Focal atrophy of the bronchial epithelium
Bronchogen
COPD
Pneumosclerosis
Cardiogen
Cor pulmonale. Pulmonary heart disease
Pancragen
Hypoxic damage of parenchymal organs

23. Therapeutic combinations of peptide regulators / CAD
Cardiosclerosis
Cardiogen
Atherosclerosis. CAD. CHF
Normoftal
Cerebrovascular disease
Bronchogen
Pulmonary perfusion disturbance
Pancragen
Hypoxic damage of parenchymal organs

24. Therapeutic combinations of peptide regulators / andropause
Testagen
Testosterone level decrease
Andropause. BPH
Normoftal
Erectile dysfunction (with combined genesis)
Pancragen
Impaired glucose tolerance
BPH.
Urination disorders
Vesilut

25. The benefits of peptide bioregulators
Peptides are obtained by biological synthesis. It excludes the presence of prions, latent or active viruses and ensures a high purity of substance
The substance is identical to the native peptide. As a result, the peptide bioregulators are hypoallergenic, safe in a wide range of doses and have no side effects
The range of application is: health improvement, prophylaxis, monotherapy or the inclusion in the treatment regimens. It allows to create an individual dosage for each customer and patient
Application of peptide regulators leads to a stable long-term results, increases the conventional therapy effectiveness and improves the life quality of the consumer or patient